Successful treatment of adult‐onset nesidioblastosis by continuous subcutaneous octreotide infusion in a patient on hemodialysis
Octreotide may be useful in noninsulinoma pancreatogenous hypoglycemia syndrome with nesidioblastosis patients who was on hemodialysis. Continuous octreotide subcutaneous infusion can reduce side‐effects and stabilize plasma glucose levels.